SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
DUBLIN, Ireland, Sept. 22, 2016 -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development, and commercialization of novel protein immunotherapies, today announced that members of its management team will discuss the Phase 2 development strategy for PRX003, the antibody in development for the potential treatment of inflammatory diseases, including psoriasis, during a webcast on September 29.
Conference Call and Webcast Details
Prothena management will provide an overview of PRX003, a novel antibody that targets CD146 (or melanoma cell adhesion molecule, MCAM) and discuss its Phase 2 development strategy during a live audio webcast and conference call on September 29, 2016, at 4:30 PM EDT. The webcast and slide presentation will be made available on the company's website at www.prothena.com under the Investors tab in the Events and Presentations section.
To access the conference call via dial-in, please dial (877) 887-5215 (U.S. toll free) or (315) 625-3069 (international) five minutes prior to the start time and refer to conference ID number 83102616. A replay of the webcast and call will be available for at least 90 days via dial-in at (855) 859-2056 (U.S. toll free) or (404) 537-3406 (international), Conference ID Number 83102616.
About Prothena
Prothena Corporation plc is a global, late-stage clinical biotechnology company seeking to fundamentally change the course of progressive diseases with its clinical pipeline of novel therapeutic antibodies. Fueled by its deep scientific understanding built over decades of research in protein misfolding and cell adhesion — the root causes of many serious or currently untreatable amyloid and inflammatory diseases — Prothena has advanced several drug candidates into clinical trials while pursuing discovery of additional novel therapies. Our pipeline of antibody-based product candidates targets a number of potential indications including AL amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), inflammatory diseases, including psoriasis (PRX003), and ATTR amyloidosis (PRX004). For more information, please visit the company's web site at www.prothena.com.
Contacts Investors: Tran Nguyen, CFO 650-837-8535, [email protected] Media: Ellen Rose 650-922-2405, [email protected]
